HomeCompareBDGSF vs JNJ

BDGSF vs JNJ: Dividend Comparison 2026

BDGSF yields 4.44% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDGSF wins by $3161.86M in total portfolio value
10 years
BDGSF
BDGSF
● Live price
4.44%
Share price
$134.25
Annual div
$5.96
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3161.89M
Annual income
$3,030,657,588.63
Full BDGSF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BDGSF vs JNJ

📍 BDGSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDGSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDGSF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDGSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDGSF
Annual income on $10K today (after 15% tax)
$377.09/yr
After 10yr DRIP, annual income (after tax)
$2,576,058,950.34/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BDGSF beats the other by $2,576,054,964.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDGSF + JNJ for your $10,000?

BDGSF: 50%JNJ: 50%
100% JNJ50/50100% BDGSF
Portfolio after 10yr
$1580.96M
Annual income
$1,515,331,139.01/yr
Blended yield
95.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BDGSF
No analyst data
Altman Z
0.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDGSF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDGSFJNJ
Forward yield4.44%2.13%
Annual dividend / share$5.96$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$3161.89M$30.3K
Annual income after 10y$3,030,657,588.63$4,689.40
Total dividends collected$3152.60M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BDGSF vs JNJ ($10,000, DRIP)

YearBDGSF PortfolioBDGSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,587$887.28$10,592$272.30+$995.00BDGSF
2$14,320$1,921.70$11,289$357.73+$3.0KBDGSF
3$19,762$4,439.12$12,123$472.89+$7.6KBDGSF
4$32,595$11,450.38$13,141$629.86+$19.5KBDGSF
5$70,179$35,301.95$14,408$846.81+$55.8KBDGSF
6$217,160$142,068.08$16,021$1,151.60+$201.1KBDGSF
7$1,054,064$821,703.07$18,122$1,588.22+$1.04MBDGSF
8$8,582,874$7,455,025.47$20,930$2,228.20+$8.56MBDGSF
9$122,648,484$113,464,809.63$24,792$3,191.91+$122.62MBDGSF
10$3,161,891,467$3,030,657,588.63$30,274$4,689.40+$3161.86MBDGSF

BDGSF vs JNJ: Complete Analysis 2026

BDGSFStock

Bank of Georgia Group PLC, through its subsidiaries, provides various banking products and services primarily in Georgia. It operates through three segments: Retail Banking, Corporate and Investment Banking, and BNB. The Retail Banking segment offers consumer loans, mortgage loans, overdrafts, credit cards, and other credit facilities; funds transfer and settlement services; and customers' deposits for individuals and legal entities under the Express, Bank of Georgia, MSME, and SOLO brands. It primarily serves retail, and mass retail and affluent segments, as well as small and medium enterprises, and micro businesses. The Corporate Investment Banking segment provides loans and other credit facilities, funds transfers and settlement services, trade finance services, and documentary operations support services; and handles saving and term deposits for corporate and institutional customers. This segment also offers private banking services to high net worth clients; and brokerage services. The BNB segment provides retail and corporate banking services to clients in Belarus. As of September 30, 2022, the company operated 211 retail branches, 994 automated teller machines, and 3,152 Express Pay terminals. Bank of Georgia Group PLC was incorporated in 2017 and is headquartered in London, the United Kingdom.

Full BDGSF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BDGSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDGSF vs SCHDBDGSF vs JEPIBDGSF vs OBDGSF vs KOBDGSF vs MAINBDGSF vs ABBVBDGSF vs MRKBDGSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.